...
首页> 外文期刊>Neurotoxicology >Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: Mitochondrial dysfunction and neurodegeneration
【24h】

Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: Mitochondrial dysfunction and neurodegeneration

机译:3-硝基丙酸蛋白酶抑制剂的潜力诱导亨廷顿病等症状:线粒体功能障碍和神经变性

获取原文
获取原文并翻译 | 示例
           

摘要

Huntington's disease (HD) is a genetic, neurodegenerative disorder mainly characterized by motor dysfunction, cognitive decline and psychiatric disturbances. 3-Nitropropionic acid (3-NP) is an inhibitor of succinate dehydrogenase (Complex II) of the mitochondrial respiratory chain, which thereby reduces production of ATP. It induces neurotoxicity by causing striatal degeneration, energy deficit and oxidative stress. Angiotensin converting enzyme (ACE) is an important protease in the renin angiotensin system (RAS) responsible for the conversion of Angiotensin I to Angiotensin II. Angiotensin-II stimulates mitochondrial oxidant release leading to depression of energy metabolism. ACE inhibitors have shown promise in disorders like stress, anxiety, and depression in addition to showing beneficial effects in cognitive disorders like Alzheimer's. Angiotensin-II inhibition enhances energy production by lowering mitochondrial oxidant production, and hence protects mitochondrial structure. Trandolapril is a centrally active ACE inhibitor. 3-NP administered systematically (20 mg/kg, i.p) for 4 days consecutively induced HD like symptoms - loss of body weight, neurobehavioral alterations like memory dysfunction (elevated plus maze, Morris water maze performance), Hind-limb impairment (Narrow beam test), motor incoordination (locomotor activity). Biochemical studies on brain tissue showed increased lipid peroxidation, nitrite levels and acetylcholinesterase activity along with decreased levels of reduced glutathione, catalase activity. Mitochondrial enzyme complex activities (I, II, IV and MTT assay) were found to be significantly lowered in brain mitochondria. Administration of Trandolapril (4 and 6 mg/kg, p.o) daily for 12 days showed significant improvement in body weight, neurobehavioral parameters, oxidative stress and mitochondrial enzyme activities in rat brain. These findings were further confirmed by histopathological studies which showed improvement in 3-NP induced brain lesions. This study indicates that Trandolapril could be an effective treatment option for the management of HD. (C) 2014 Elsevier Inc. All rights reserved.
机译:亨廷顿的疾病(HD)是一种遗传,神经退行性疾病主要是通过运动功能障碍,认知下降和精神扰动的特征。 3-硝基丙酸(3-NP)是线粒体呼吸链的琥珀酸脱氢酶(复合物II)的抑制剂,从而减少了ATP的产生。它通过引起纹状体变性,能量缺损和氧化应激来诱导神经毒性。血管紧张素转化酶(ACE)是肾素血管紧张素系统(RAS)中的重要蛋白酶,其负责血管紧张素I转化为血管紧张素II。血管紧张素-II刺激线粒体氧化剂释放,导致能量代谢的抑郁。 ACE抑制剂除了显示在阿尔茨海默氏症等认知障碍中的有益效果之外,患有压力,焦虑和抑郁等疾病的承诺。血管紧张素-II抑制通过降低线粒体氧化剂产生来增强能量产生,因此保护线粒体结构。 Trandolapril是一个中央活性ACE抑制剂。 3-NP系统地(20mg / kg,IP)施用4天,连续诱导HD,如症状 - 体重损失,神经表达改变如记忆功能障碍(升高加上迷宫,莫里斯水迷宫性能),后肢损伤(窄梁测试),电机无法解决(机车活动)。对脑组织的生化研究显示出增加的脂质过氧化,亚硝酸盐水平和乙酰胆碱酯酶活性以及降低的谷胱甘肽,过氧化氢酶活性的水平降低。在脑线粒体中发现线粒体酶复合体(I,II,IV和MTT测定)在脑线粒体中显着降低。每天进行Trandolapril(4和6mg / kg,p.o)的施用12天显示大鼠大鼠体重,神经兽性参数,氧化应激和线粒体酶活性的显着改善。通过组织病理学研究进一步证实了这些发现,其显示出3-NP诱导的脑病变的改善。本研究表明,Trandolapril可能是HD管理的有效治疗选择。 (c)2014年elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号